Literature DB >> 20362389

Induction of cell death in neuroblastoma by inhibition of cathepsins B and L.

Rita Colella1, Guizhen Lu, Lisa Glazewski, Bruce Korant, Anjan Matlapudi, Matthew R England, Colin Craft, Christopher N Frantz, Robert W Mason.   

Abstract

A specific irreversible inhibitor of both cathepsins B and L, Fmoc-Tyr-Ala-CHN(2) (FYAD) induced apoptosis of neuroblastoma cells but not other tumor cells. Cysteine protease inhibitors that were not efficient inhibitors of both proteases did not cause death of any cell line tested. Apoptosis was preceded by accumulation of large electron dense vesicles and multivesicular bodies in the cytoplasm. Exposure of cells to the cathepsin D inhibitor, pepstatin, failed to rescue cells from FYAD-induced death. These results indicate that inhibition of cathepsins B and L may provide a unique mechanism for selectively inducing death of neuroblastoma with limited toxicity to normal cells and tissues. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362389      PMCID: PMC2883669          DOI: 10.1016/j.canlet.2010.01.037

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  51 in total

1.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs.

Authors:  M Bogyo; S Verhelst; V Bellingard-Dubouchaud; S Toba; D Greenbaum
Journal:  Chem Biol       Date:  2000-01

2.  Cathepsins B and L are markers for clinically invasive types of meningiomas.

Authors:  T Strojnik; B Zidanik; J Kos; T T Lah
Journal:  Neurosurgery       Date:  2001-03       Impact factor: 4.654

3.  Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells.

Authors:  S Mohanam; S L Jasti; S R Kondraganti; N Chandrasekar; S S Lakka; Y Kin; G N Fuller; A W Yung; A P Kyritsis; D H Dinh; W C Olivero; M Gujrati; F Ali-Osman; J S Rao
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

4.  S2' substrate specificity and the role of His110 and His111 in the exopeptidase activity of human cathepsin B.

Authors:  Joanne C Krupa; Sadiq Hasnain; Dorit K Nägler; Robert Ménard; John S Mort
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  An intracellular form of cathepsin B contributes to invasiveness in cancer.

Authors:  A M Szpaderska; A Frankfater
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

6.  A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia.

Authors:  D M Seyfried; R Veyna; Y Han; K Li; N Tang; R L Betts; S Weinsheimer; M Chopp; J Anagli
Journal:  Brain Res       Date:  2001-05-18       Impact factor: 3.252

7.  Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells.

Authors:  L J Wainwright; A Lasorella; A Iavarone
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

8.  Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas.

Authors:  Roberta Castino; Deborah Pace; Marina Démoz; Marco Gargiulo; Chiara Ariatta; Elisabetta Raiteri; Ciro Isidoro
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

9.  Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells.

Authors:  D M Zhu; F M Uckun
Journal:  Leuk Lymphoma       Date:  2000-10

10.  Effects of cathepsins B and L inhibition on postischemic protein alterations in the brain.

Authors:  John Anagli; Kadija Abounit; Paul Stemmer; Yuxia Han; Lisa Allred; Shantel Weinsheimer; Ashkhen Movsisyan; Donald Seyfried
Journal:  Biochem Biophys Res Commun       Date:  2007-12-03       Impact factor: 3.575

View more
  9 in total

Review 1.  Multivesicular bodies in neurons: distribution, protein content, and trafficking functions.

Authors:  Christopher S Von Bartheld; Amy L Altick
Journal:  Prog Neurobiol       Date:  2011-01-07       Impact factor: 11.685

Review 2.  Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes.

Authors:  Reik Löser; Jens Pietzsch
Journal:  Front Chem       Date:  2015-06-23       Impact factor: 5.221

3.  Effect of EGb761 on light-damaged retinal pigment epithelial cells.

Authors:  Yun-Yun Zhou; Chang-Zheng Chen; Yu Su; Lu Li; Zuo-Hui-Zi Yi; Hang Qi; Ming Weng; Yi-Qiao Xing
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

4.  Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells.

Authors:  Donna M Cartledge; Rita Colella; Lisa Glazewski; Guizhen Lu; Robert W Mason
Journal:  Invest New Drugs       Date:  2012-05-02       Impact factor: 3.850

Review 5.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.

Authors:  Oakley C Olson; Johanna A Joyce
Journal:  Nat Rev Cancer       Date:  2015-12       Impact factor: 60.716

6.  Cathepsin Inhibition Prevents Autophagic Protein Turnover and Downregulates Insulin Growth Factor-1 Receptor-Mediated Signaling in Neuroblastoma.

Authors:  Mehrnoosh Soori; Guizhen Lu; Robert W Mason
Journal:  J Pharmacol Exp Ther       Date:  2015-12-10       Impact factor: 4.030

7.  Activation of liver X receptor decreases BACE1 expression and activity by reducing membrane cholesterol levels.

Authors:  Weigang Cui; Yan Sun; Zhongping Wang; Chongchong Xu; Li Xu; Fei Wang; Zulin Chen; Yuwen Peng; Ruixi Li
Journal:  Neurochem Res       Date:  2011-06-01       Impact factor: 3.996

Review 8.  Targeting lysosomes in human disease: from basic research to clinical applications.

Authors:  Mengdie Cao; Xiangyuan Luo; Kongming Wu; Xingxing He
Journal:  Signal Transduct Target Ther       Date:  2021-11-08

9.  Antioxidant and anti-protease activities of diazepinomicin from the sponge-associated Micromonospora strain RV115.

Authors:  Usama Ramadan Abdelmohsen; Matthias Szesny; Eman Maher Othman; Tanja Schirmeister; Stephanie Grond; Helga Stopper; Ute Hentschel
Journal:  Mar Drugs       Date:  2012-10-08       Impact factor: 6.085

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.